← Back to Search

Photo-activation of Riboflavin

Crosslinking for Corneal Neovascularization

Price Vision Group, Indianapolis, IN

30 minute photoactivation of riboflavin 0.1% +1 morePhase 2 & 3RecruitingLed by Francis W Price, Jr., MDResearch Sponsored by Price Vision Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up6 months

Awards & highlights

No Placebo-Only Group

Study Summary

This trial will test if a light-activated vitamin can safely and effectively treat an eye condition that causes new blood vessels to grow.

Eligible Conditions

Corneal Neovascularization

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

corneal neovascularization as a proportion of the total corneal area

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: 10 minute photoactivationActive Control1 Intervention

photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes

Group II: 30 minute photoactivationActive Control1 Intervention

photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Price Vision GroupLead Sponsor

10 Previous Clinical Trials

1,521 Total Patients Enrolled

Cornea Research Foundation of AmericaOTHER

7 Previous Clinical Trials

2,957 Total Patients Enrolled

Francis W Price, Jr., MDPrincipal InvestigatorPrice Vision Group

5 Previous Clinical Trials

3,386 Total Patients Enrolled

Media Library

10 minute photoactivation of riboflavin 0.1% (Photo-activation of Riboflavin) Clinical Trial Eligibility Overview. Trial Name: NCT04787471 — Phase 2 & 3

Corneal Neovascularization Research Study Groups: 10 minute photoactivation, 30 minute photoactivation

Corneal Neovascularization Clinical Trial 2023: 10 minute photoactivation of riboflavin 0.1% Highlights & Side Effects. Trial Name: NCT04787471 — Phase 2 & 3

10 minute photoactivation of riboflavin 0.1% (Photo-activation of Riboflavin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04787471 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does 30 minute photoactivation therapy usually target?

"30 minute photoactivation can be used for a variety of conditions, such as vitamin deficiency, joint pain, and vitamin supplementation."

Answered by AI

Are there any other research studies that use 30 minute photoactivation?

"As of now, there are 20 trials being run studying 30 minute photoactivation. 11 of those active studies are in Phase 3. While the majority of studies for 30 minute photoactivation are based in San Francisco, California, there are 47 locations running trials for this treatment."

Answered by AI

How many participants will be taking part in this experiment?

"That is correct. The listing on clinicaltrials.gov makes it clear that this study is still recruiting patients. The trial was first announced on May 3rd, 2021 and was last updated on July 27th, 2022. Currently, the research team is looking for 62 individuals from a single site."

Answered by AI

Are new participants being taken in for this experiment?

"That is correct, the listing on clinicaltrials.gov currently says that this study is open for recruitment. This specific trial was first announced on May 3rd, 2021 and was last updated on July 27th, 2022. They are 62 patients needed in total from 1 site."

Answered by AI

Recent research and studies

OphthalmologyJournal

U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia After Refractive Surgery

Hersh, Peter S., R. Doyle Stulting, David Muller, Daniel S. Durrie, Rajesh K. Rajpal, Perry S. Binder, Eric D. Donnenfeld, et al.. 2017. “U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia After Refractive Surgery”. Ophthalmology. Elsevier BV. doi:10.1016/j.ophtha.2017.05.036.

OphthalmologyJournal

United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment

Hersh, Peter S., R. Doyle Stulting, David Muller, Daniel S. Durrie, Rajesh K. Rajpal, Perry S. Binder, Eric D. Donnenfeld, et al.. 2017. “United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment”. Ophthalmology. Elsevier BV. doi:10.1016/j.ophtha.2017.03.052.

OphthalmologyJournal

Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia

Price, Marianne O., Kelly Fairchild, Matthew T. Feng, and Francis W. Price Jr.. 2018. “Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia”. Ophthalmology. Elsevier BV. doi:10.1016/j.ophtha.2017.10.034.

CorneaJournal